• News
SITC 2021, NI-2601 & NI-2901 bispecific antibody programs

SITC 2021, NI-2601 & NI-2901 bispecific antibody programs


36th Annual Meeting & Pre-Conference Programs (SITC)

WASHINGTON, D.C/ SOCIETY FOR IMMUNOTHERAPY OF CANCER/ NOV.10-14, 2021 /

Light Chain Bioscience is very pleased to have Xavier Chauchet attend in-person the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 10-14, 2021 in Washington DC.

Xavier will present our innovative and differentiating CD47xPD-L1 bispecific antibodies for a simultaneous blockade of PD-1/PD-L1 and CD47/SIRPa immune checkpoint axes, NI-2601 and NI-2901. The programs are currently in late discovery phase and clinical lead candidates have been identified.

The poster entitled “CD47xPD-L1 bispecific antibodies for cancer therapy” (#265) will be exposed and presented on Nov. 12 between 9:55-10:10 a.m., 12:40-14:10 p.m., 4:35-4:50 p.m. and 7:00-8:30 p.m. and available on the SITC virtual meeting ePoster platform from 7 a.m. on Friday, Nov.12.

Read poster [PDF] :

sitc 2021 ni 2601 ni 2901 bispecific antibody programs 0


Walter E. Washington Convention Center

801 Mt Vernon Pl NW, Washington,
DC 20001, United States

+1 202-249-3000

First patient dosed with NILK-2301 in Phase I clinical trial

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer


Read more

LinkedIn